The Billion-Dollar Blind Spot: Why Global Pharma Needs Immutable ESG Data
A factual business case exploring why pharmaceutical leaders must adopt immutable data architectures to comply with strict SBTi and CSRD requirements, avoiding devastating market revocations.
Read Full Article